Clinical research progress on the efficacy and safety of bevacizumab in treating ad-vanced non-small cell lung cancer
10.3969/j.issn.1000-8179.2017.03.191
- VernacularTitle:贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展
- Author:
Binbin HU
;
Baoqing CHEN
;
You LU
- Keywords:
non-small cell lung cancer;
bevacizumab;
chemotherapy;
target therapy;
maintenance therapy;
safety
- From:
Chinese Journal of Clinical Oncology
2017;44(3):129-135
- CountryChina
- Language:Chinese
-
Abstract:
Antiangiogenesis therapy is one of the most common anticancer therapies. Bevacizumab is a monoclonal antibody that blocks the binding of the vascular endothelial growth factor to its high-affinity receptors. It is the only antiangiogenic agent approved for the first-line treatment of advanced non-small cell lung cancer (NSCLC). Many recent studies have attempted to determine the suit-able partners of bevacizumab in first-line treatment of NSCLC and evaluate its efficacy and safety as a second-line or beyond and con-tinuous treatment of beyond disease progression in patients with advanced NSCLC. This review summarizes current clinical research about the efficacy and safety of bevacizumab in the treatment of advanced NSCLC.
